Ousia Pharma Secures Substantial Seed Financing Led by Omega Funds to Advance Groundbreaking Obesity Treatment

Published on 08/07/2025 at 18:04 | prnewswire.co.uk

Ousia Pharma and Omega Funds Denmark Finland France Germany Netherlands Sweden United Kingdom Massachusetts

Pioneering a first-in-class drug-targeting approach that leverages hormone analogues to deliver small-molecule neuroplasticity modulators directly to the brain's appetite control centersFinancing will support the development of a dual-incretin-NMDA receptor antagonist conjugate through preclinical and early clinical development for the treatment of obesityfor additional information.

Contacts

Ousia Pharma
Anders Bue Klein
Co-founder & CEO, Ousia Pharma
E-mail: abk@ousiapharma.com

Omega Funds
Otello Stampacchia
Managing Director, Omega Funds
E-mail: OS@omegafunds.com